Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) and Yarrow Bioscience (NASDAQ:YARW – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.
Profitability
This table compares Zenas BioPharma and Yarrow Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zenas BioPharma | N/A | -122.45% | -58.04% |
| Yarrow Bioscience | -4,726.21% | -84.40% | -77.68% |
Valuation and Earnings
This table compares Zenas BioPharma and Yarrow Bioscience”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zenas BioPharma | $1.00 million | 1,697.21 | -$377.74 million | ($8.99) | -2.90 |
| Yarrow Bioscience | $570,000.00 | 63.48 | -$26.48 million | ($14.64) | -0.93 |
Yarrow Bioscience has lower revenue, but higher earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings for Zenas BioPharma and Yarrow Bioscience, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zenas BioPharma | 1 | 2 | 6 | 0 | 2.56 |
| Yarrow Bioscience | 1 | 0 | 2 | 0 | 2.33 |
Zenas BioPharma presently has a consensus price target of $46.71, suggesting a potential upside of 79.39%. Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 327.98%. Given Yarrow Bioscience’s higher probable upside, analysts plainly believe Yarrow Bioscience is more favorable than Zenas BioPharma.
Risk & Volatility
Zenas BioPharma has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Comparatively, Yarrow Bioscience has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.
Institutional & Insider Ownership
83.8% of Yarrow Bioscience shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Zenas BioPharma beats Yarrow Bioscience on 8 of the 14 factors compared between the two stocks.
About Zenas BioPharma
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
About Yarrow Bioscience
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
